Similar Search Results

Real Economics Needs to Reflect Real Decisions: A Response to Johnson

Sculpher, Mark; Claxton, Karl - In: PharmacoEconomics 30 (2012) 2, pp. 133-136

Persistent link: https://www.econbiz.de/10010614392

Subgroups and Heterogeneity in Cost-Effectiveness Analysis

Sculpher, Mark - In: PharmacoEconomics 26 (2008) 9, pp. 799-806

The National Institute for Health and Clinical Excellence (NICE) is required to consider cost effectiveness when issuing guidance about the use of health technologies within the UK NHS. Cost effectiveness is a means of supporting a system objective of maximizing population health gain from the...

Persistent link: https://www.econbiz.de/10005449021

Better Analysis for Better Decisions: Has Pharmacoeconomics Come of Age?

Drummond, Michael; Sculpher, Mark - In: PharmacoEconomics 24 (2006) 2, pp. 107-108

Persistent link: https://www.econbiz.de/10005449299

NICE's 2008 Methods Guide: Sensible Consolidation or Opportunities Missed?

Sculpher, Mark - In: PharmacoEconomics 26 (2008) 9, pp. 721-724

DOI: 10.2165/0019053-200826090-00001

Persistent link: https://www.econbiz.de/10005590362

Single Technology Appraisal at the UK National Institute for Health and Clinical Excellence: A Source of Evidence and Analysis for Decision Making Internationally

Sculpher, Mark - In: PharmacoEconomics 28 (2010) 5, pp. 347-349

Persistent link: https://www.econbiz.de/10008620569